Key result
Genetic evidence supports a causal role of elevated plasma triglycerides in the development of coronary heart disease.
Why the study?
Do genetic variants affecting plasma triglycerides have a causal role in coronary heart disease?
Do genetic variants affecting plasma triglycerides have a causal role in coronary heart disease?
Answers are grounded in this paper and cite their sources.
This editorial highlights genetic evidence supporting a causal relationship between plasma triglycerides and coronary heart disease.
An elevated plasma level of low-density lipoprotein (LDL) cholesterol is a major risk factor for coronary heart disease. Whether an elevated plasma triglyceride level and a reduced level of high-density lipoprotein (HDL) cholesterol also carry an increased risk of coronary heart disease has remained a contentious issue.1Two groups of investigators now describe in the Journal important genetic evidence showing a causal role of plasma triglycerides in coronary heart disease. Stitziel and colleagues2 tested 54,003 coding-sequence variants covering 13,715 human genes in more than 72,000 patients with coronary artery disease and 120,000 controls. Dewey and colleagues3 sequenced the exons of . . .
No takes yet. Share an insight, caveat, or question.
Sander Kersten (2016) conducted an editorial in Coronary heart disease (n=192,000). Plasma triglycerides (genetic variants) was evaluated on Coronary heart disease. Genetic evidence supports a causal role of elevated plasma triglycerides in the development of coronary heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: